I-Mab (IMAB) announced that on June 11, 2025 it received notification from The Nasdaq Stock Market notifying the Company that it had regained compliance with Nasdaq’s $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The Company’s American Depositary Shares will continue to be listed and traded on Nasdaq. To regain compliance with the Listing Rule, the Company’s ADSs were required to maintain a minimum closing bid price of $1.00 for at least 10 consecutive business days, which was achieved on June 10, 2025. Nasdaq has stated that this matter is now closed.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMAB:
- I-Mab Advances Givastomig in Gastric Cancer with Promising Clinical Data
- I-MAB Strengthens Board with New Appointment of Dr. Sean Cao
- I-Mab initiated with a Buy at Lucid Capital
- I-Mab’s Financial Report Highlights Givastomig Progress
- I-Mab’s Promising Clinical Developments and Financial Stability Earn ‘Buy’ Rating from Analyst